NasdaqGS - Nasdaq Real Time Price USD

Cogent Biosciences, Inc. (COGT)

6.01 -0.53 (-8.10%)
At close: April 25 at 4:00 PM EDT
5.50 -0.51 (-8.49%)
After hours: April 25 at 7:30 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Andrew R. Robbins M.B.A. President, CEO & Director 1.06M -- 1976
Dr. John Edward Robinson Ph.D. Chief Scientific Officer 749.89k -- 1975
Dr. Jessica Sachs M.D. Chief Medical Officer 773.92k -- 1975
Mr. John L. Green C.A., CPA CFO & Principal Accounting Officer 763.99k -- 1980
Mr. Brad Barnett Chief Technology Officer -- -- --
Christi Waarich Senior Director of Investor Relations -- -- --
Mr. Evan D. Kearns J.D. Chief Legal Officer & Corporate Secretary -- -- 1980
Ms. Erin Schellhammer Chief People Officer -- -- --
Mr. Dana R. Martin Pharm.D. Senior Vice President of Medical Affairs -- -- --
Brad Fell Senior Vice President of Chemistry -- -- --

Cogent Biosciences, Inc.

275 Wyman Street
3rd Floor
Waltham, MA 02451
United States
617 945 5576 https://www.cogentbio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
164

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Cogent Biosciences, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
Cogent Biosciences, Inc. Earnings Call

Related Tickers

SYRE Spyre Therapeutics, Inc.
32.47
-1.58%
 
VRDN Viridian Therapeutics, Inc.
12.70
-2.53%
 
TVTX Travere Therapeutics, Inc.
5.39
-1.10%
 
NAMS NewAmsterdam Pharma Company N.V.
21.44
-1.65%
 
HOWL Werewolf Therapeutics, Inc.
6.21
-2.82%
 
TYRA Tyra Biosciences, Inc.
15.11
-5.56%
 
LXEO Lexeo Therapeutics, Inc.
12.16
-2.72%
 
VALN Valneva SE
7.55
-5.03%
 
MGTX MeiraGTx Holdings plc
4.7100
-3.09%
 
CGEM Cullinan Therapeutics, Inc.
19.25
+1.91%